Search

Zai Lab Ltd ADR

Закрыт

СекторЗдравоохранение

25.68 -0.54

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

25.53

Макс.

25.72

Ключевые показатели

By Trading Economics

Доход

191K

-51M

Продажи

6.7M

106M

Прибыль на акцию

-0.46

Рентабельность продаж

-47.808

Сотрудники

1,784

EBITDA

-2.1M

-46M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+53.05% upside

Дивиденды

By Acuity

Следующий отчет о доходах

5 нояб. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

737M

2.8B

Предыдущая цена открытия

26.22

Предыдущая цена закрытия

25.68

Новостные настроения

By Acuity

38%

62%

77 / 339 Рейтинг в Healthcare

Zai Lab Ltd ADR График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

18 сент. 2026 г., 23:41 UTC

News

Iovance Biotherapeutics granted inducement stock options for 179.75k shares to new employees, contributing to a modest decline in after-market hours.

18 сент. 2026 г., 23:31 UTC

News

BlackRock Inc. shares are modestly lower in after-market trading amid heightened legal concerns as the DOJ considers intervention in an antitrust lawsuit against the company.

18 сент. 2026 г., 23:26 UTC

News

State Street Corp declines in after-market trading as the U.S. Department of Justice considers intervention in a state antitrust lawsuit regarding energy price inflation.

18 сент. 2026 г., 23:16 UTC

News

Union Pacific Corp's stock is trading higher in after-market hours following UBS's upgrade to Buy and a price target increase to $339, citing expected cargo growth.

18 сент. 2026 г., 23:11 UTC

News

AutoNation Inc has been downgraded from Buy to Hold amid industry challenges, yet the stock is rising in after-market trading as the broader market advances.

18 сент. 2026 г., 23:11 UTC

News

Leidos Holdings Inc. has secured an $85 million contract from the U.S. Department of War for aerospace systems design, with shares rising in after-market trading.

18 сент. 2026 г., 23:06 UTC

News

AbbVie Inc. is experiencing a slight decline in after-market trading, positioned near the lower end of its recent trading range despite promising myeloma study results.

18 сент. 2026 г., 23:06 UTC

News

Boeing is in talks with NASA to expand its Starliner program, potentially adding ten or more flights, as the stock moves higher in after-hours trading.

18 сент. 2026 г., 23:06 UTC

News

Chevron Corp has declined in after-market trading, despite Goldman Sachs raising its price target to $240 and Piper Sandler setting an even higher target of $243.

18 сент. 2026 г., 23:06 UTC

News

Okta Inc appointed Helen Riley to its board, enhancing leadership as shares rise in after-market trading, aligning with a broader market advance.

18 сент. 2026 г., 23:06 UTC

News
Social Media

Nike shares are advancing in after-market hours despite recent challenges, including a significant decline and hitting a 12-year low.

18 сент. 2026 г., 23:06 UTC

News

General Motors Co is advancing in after-market trading following its decision to reinstate Apple’s CarPlay and Android Auto in its vehicles.

18 сент. 2026 г., 23:06 UTC

News

Medtronic PLC raised its fiscal 2027 profit forecast and reported first-quarter revenue of $9.756 billion, exceeding expectations, in after-market trading.

18 сент. 2026 г., 23:06 UTC

News

RTX Corp's backlog hit a record $289 billion, with the stock advancing in after-market trading, despite remaining below its 20-day moving average.

18 сент. 2026 г., 23:06 UTC

News

Celsius Holdings Inc shares are higher in after-market trading, continuing a positive trend despite ongoing legal scrutiny over its Alani Nu product line.

18 сент. 2026 г., 23:01 UTC

News
Social Media

Northrop Grumman targets $10 billion in annual international sales by 2031, while shares trade lower in after-market hours.

18 сент. 2026 г., 23:01 UTC

News

Kimberly-Clark Corp plans to divest assets related to its $40 billion Kenvue acquisition to address EU antitrust concerns, with shares modestly higher in after-market trading.

18 сент. 2026 г., 23:01 UTC

Social Media
News

Accenture PLC announced a $1 billion partnership with Anthropic to enhance AI evaluation capabilities, leading to a sharp advance in shares during after-market hours.

18 сент. 2026 г., 23:01 UTC

News

Bitcoin is sharply higher, trading well above its previous close amid a rally in the cryptocurrency market, driven by strong investor sentiment and recent Fed announcements.

18 сент. 2026 г., 23:01 UTC

News

Ethereum is advancing sharply, continuing its upward trajectory alongside a broader cryptocurrency rally, despite earlier pulling back from a session high.

18 сент. 2026 г., 23:01 UTC

News

Ethereum is advancing sharply, remaining significantly higher since Thursday's close, as the cryptocurrency market rallies alongside Bitcoin surpassing $81k.

18 сент. 2026 г., 23:01 UTC

News

Sharply higher amid strong investor sentiment and Fed announcements.

18 сент. 2026 г., 23:01 UTC

News
Social Media

Wendy's Co shares are trading modestly higher in after-market hours despite concerns over Meritage Hospitality Group's Chapter 11 bankruptcy filing affecting 314 locations.

18 сент. 2026 г., 22:51 UTC

News

Lockheed Martin Corp receives an $871.2 million contract modification for F-35 support, contributing to a modest after-market hours gain.

18 сент. 2026 г., 22:51 UTC

News

Hf Foods Group Inc. has terminated its $100 million at-the-market equity offering program, leading to a sharp decline in after-market trading.

18 сент. 2026 г., 22:01 UTC

News

Simply Good Foods Co is facing a securities fraud class action lawsuit, contributing to a modest decline in after-market trading following concerns over OWYN's sales performance.

18 сент. 2026 г., 21:41 UTC

News

Amneal Pharmaceuticals received FDA approval for its lanreotide injection, launching the product immediately, driving shares higher in after-market hours.

18 сент. 2026 г., 21:03 UTC

Macro News
News
Macro Event

The Bank of Japan raised its key interest rate to 1.25%, boosting the USD/JPY pair, which is trading higher above Thursday's close.

18 сент. 2026 г., 21:01 UTC

News

Navient Corp is seeing a modest increase in after-market trading, reflecting routine performance and placing the price around the middle of its one-month range.

18 сент. 2026 г., 21:01 UTC

News
Macro Event
Correlated Moves

The Bank of Japan raised its key short-term interest rate to 1.25%, causing GBP/JPY to trade modestly higher, though still below its 20-day moving average.

Сравнение c конкурентами

Изменение цены

Zai Lab Ltd ADR Прогноз

Целевая цена

By TipRanks

53.05% рост

Прогноз на 12 месяцев

Средняя 39.333 USD  53.05%

Максимум 45 USD

Минимум 36 USD

Основано на мнении 3 аналитиков Wall Street, спрогнозировавших целевые цены для Zai Lab Ltd ADR на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

3 ratings

3

Покупка

0

Удержание

0

Продажа

Настроения

By Acuity

77 / 339Рейтинг в Здравоохранение

Новостные настроения

Свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.